The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will ...

Acelyrin was explicit that it had made the changes in response to the “continued rapid accumulation” of 8.8% of the biotech’s stock by Tang Capital Partners. Acelyrin had already turned down ...

This is yet another biopharma targeted by Concentra Biosciences, the holdco of Tang Capital. To get you up to speed, here is a brief timeline of events that have led to the current setup ...

But a curveball from Concentra could change all that. The Tang Capital Partners-owned biotech has offered to buy all outstanding shares of Acelyrin for $3 per share in cash, along with a ...

LOS ANGELES - Acelyrin Inc. (NASDAQ: SLRN), a biopharmaceutical company specializing in immunology treatments, has implemented a stockholder rights plan following Tang Capital Partners ...

Presently, Tang, via his hedge fund Tang Capital Partners and his privately held shell company, Concentra Biosciences, has a $3-per-share cash offer on the table to acquire and shut down ...